---

Carsten Brockmeyer

Chief Executive Officer, Formycon

Carsten has been working with the biosimilars industry from the very beginning; he was involved in the development of Binocrit (epoetin alfa), the world’s first complex biosimilar anemia drug. He was headhunted for the role at Formycon after holding a one-day workshop on biosimilars at the company. 

---

Part of the Power List 2016

The Top 100

The nominations are in and after considerable debate and analysis from our judging panel, we present The Power List 2016 – our second foray into the Top 100 most influential people in the world of drug development and manufacture.

Go to The Power List 2016